[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Kim YJ, Lee YC, Kim JH, Chung JB, Kim SK: Advanced gastric cancer showing complete remission of metastatic lymph node after chemotherapy. Gut Liver; 2007 Jun;1(1):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced gastric cancer showing complete remission of metastatic lymph node after chemotherapy.
  • A 69-year-old woman with dyspepsia and poor oral intake was diagnosed as advanced gastric cancer.
  • Clinical staging was stage IV with inoperable status, and thus, three cycles of palliative chemotherapy with paclitaxel and cisplatin were performed.
  • Follow up endoscopy and positron emission tomography with computed tomography (PET-CT) revealed marked decrease in the primary stomach lesion and metastatic lymph nodes.
  • Distal gastrectomy and D2 lymph node dissection were performed with gastrojejunostomy.
  • However, there was no pathologic evidence of lymph node metastasis.
  • Only the necrotic areas without viable carcinoma cells were noted in regional lymph nodes located along the left gastric artery and common hepatic artery.
  • Because of the excellent response to chemotherapy, R0 resection was carried out.
  • Herein, we report a case of advanced gastric cancer showing complete remission of metastatic lymphadenopathy after palliative chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan To Kagaku Ryoho. 2005 Oct;32(10):1443-5 [16227745.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jan;33(1):99-103 [16410707.001]
  • [Cites] Anticancer Drugs. 2006 Feb;17(2):225-9 [16428942.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Apr;33(4):509-11 [16612163.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 May;33(5):667-70 [16685169.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jun;6(6):931-9 [16761937.001]
  • [Cites] Gastric Cancer. 2006;9(2):129-35 [16767369.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Aug;33(8):1163-6 [16912541.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1105-9 [16930932.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Sep;33(9):1321-3 [16969034.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):210-5 [7754625.001]
  • [Cites] Rev Gastroenterol Mex. 1997 Jul-Sep;62(3):160-6 [9480522.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Dec;32(13):2101-4 [16352936.001]
  • (PMID = 20485662.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871649
  • [Keywords] NOTNLM ; Advanced gastric cancer / Chemotherapy / Complete response
  •  go-up   go-down


2. Reichle A, Bolder U, Bataille F, Messmann H, Wagner H, Zaiss M, Wild P, Hofstädter F, Andreesen R, Jauch KW: A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease. Bone Marrow Transplant; 2003 Oct;32(7):665-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease.
  • The present multimodal treatment approach was designed to achieve prolonged tumor control in advanced gastric cancer.
  • A total of 26 patients with stage IV gastric cancer (metastatic disease n=25), ECOG performance status 0-3 and laparoscopically evaluated peritoneal status received a modified EAP schedule to prove chemosensitivity and to mobilize autologous peripheral blood stem cells (aPBSC).
  • Patients without progressive disease proceeded to tandem high-dose chemotherapy (HD-CT) and aPBSCT.
  • Of 26 patients, 20(77%) achieved partial remission after dose-intensive chemotherapy: local R0 resection was achieved in 12 out of 14 patients selected for surgery (46% of all patients).
  • The combined treatment approach is tolerable and feasible in advanced disease and opens a therapeutic window for a significant proportion of patients, even in cases with histologically proven peritoneal carcinomatosis.
  • [MeSH-major] Combined Modality Therapy / methods. Neoplasm Metastasis / prevention & control. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / toxicity. Female. Gastrectomy. Humans. Length of Stay. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation / adverse effects. Peripheral Blood Stem Cell Transplantation / methods. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13130313.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol; 2010;3:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of the American Society of Clinical Oncology with the theme of "personalizing cancer care".
  • Adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2.
  • Gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
  • Octreotide LAR significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut.
  • Addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor response but increased toxicities.
  • Bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage II or III colon cancer.
  • In patients with resected stage II colon cancer, recurrence score estimated by multigene RT-PCR assay has been shown to provide additional risk stratification.
  • In stage IV colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2011 Jul 10;29(20):2773-80 [21606427.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1140-6 [15894548.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1898-905 [16219623.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] World J Surg Oncol. 2009;7:80 [19886993.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • (PMID = 20331897.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2856525
  •  go-up   go-down


Advertisement
4. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • Free cancer cells might induce or indicate an early peritoneal seeding with a subsequent peritoneal metastasis.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • Immediately after the laparotomy, 200 ml physiologic saline, heated to 37 degrees C, was introduced into the abdominal cavity, mannualy dispersed and collected from the region around the gastric tumor and the pouch of Douglas.
  • The cytological findings were defined as positive or negative according to the presence of cancer cells.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • RESULTS: Free cancer cells were found in 24 (24%) of the patients, while in 76 (76%) of them cytological findings were negative.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • Free cancer cells were statistically more frequently (p < or = 0.05) detected in the patients with lymph nodes metastases comparing to the patients with out lymph nodes involvement.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • CONCLUSION: Peritoneal lavage cytology was shown to be a useful tool for the detection of the group of patients with greatest risk of peritoneal dissemination.
  • The frequency of positive cytological findings was highly associated with the diameter of the tumor and the cancer invasion of serosa.
  • Cytological examination of peritoneal lavage fluid improved the accuracy of staging and selection of patients who might have benefit from neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytodiagnosis. Female. Gastrectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Peritoneal Lavage. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


5. Nakamura R, Saikawa Y, Kumagai K, Kiyota T, Ohashi M, Yoshida M, Kubota T, Kumai K, Kitajima M: A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1. Int J Clin Oncol; 2007 Aug;12(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1.
  • We report the case of a 62-year-old man with advanced gastric cancer and multiple liver metastases who was successfully treated with combined chemotherapy including S-1.
  • The patient was clinically diagnosed with stage IV (T3 N2 H1 P0) disease and was initially treated with 100 mg/body per day S-1 administered orally for 21 days and 10 mg/body per day cisplatin (CDDP) infused on days 1-5, 8-12, and 15-19.
  • This chemotherapy resulted in significant reduction of the liver and gastric tumors.
  • After receiving additional CDDP/S-1 administration as an outpatient, the patient's liver masses disappeared as shown on abdominal computed tomography (CT).
  • After discharge without any surgical complication, CT revealed regrowth of the S4 liver mass, and combined docetaxel and CDDP was selected as second-line chemotherapy with local radiation therapy against the hepatic metastasis.
  • At 2 years 7 months after the initial treatment, no sign of cancer (including liver metastasis and peritoneal dissemination) has been identified by radiological follow-up examinations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Male. Middle Aged. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2001 Mar;181(3):279-83 [11376587.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii41-4 [12810457.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(5):391-9 [9771954.001]
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):89-92 [11748462.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:50-7 [12775021.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Oncology. 2001;61(1):16-22 [11474243.001]
  • [Cites] Cancer Sci. 2004 Aug;95(8):679-84 [15298732.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Surgery. 1993 Oct;114(4):799-805; discussion 804-5 [8211697.001]
  • [Cites] Oncol Rep. 2005 May;13(5):865-70 [15809751.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):203-8 [9142380.001]
  • [Cites] Oncology. 1999 Oct;57(3):202-10 [10545788.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):86-91 [11753046.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):326-9 [12402069.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2328-33 [14556924.001]
  • [Cites] J Gastroenterol. 2000 Dec;35(12):907-11 [11573726.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8 [12109800.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Oncology. 2000 Jun;59(1):14-7 [10895060.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10 (3):687-91 [12684644.001]
  • (PMID = 17701010.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Otsuki K, Saigo K, Kenmochi T, Maruyama M, Akutsu N, Iwashita C: [A case of complete response to combination therapy of S-1 and CDDP for Stage IV gastric cancer with Virchow's lymph node and para-aorta lymph node metastasis]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of complete response to combination therapy of S-1 and CDDP for Stage IV gastric cancer with Virchow's lymph node and para-aorta lymph node metastasis].
  • The patient was a 53-year-old male with Stage IV gastric cancer with Virchow's lymph node and para-aorta lymph node metastasis.
  • The chemotherapy regimen was given S-1 orally at 80 mg/m(2) day on day 1 to 21 and CDDP intravenously at 60 mg/m(2) day on day 8, repeated for 35 days.
  • After two courses and a reduced regimen with S-1 64 mg/m(2) day plus CDDP 35 mg/m(2) day, the tumor lesion became CR and the serum CEA 575 ng/mL level before therapy decreased to the normal level.
  • The patient received six courses of oral S-1(64 mg/m(2) day)for 28 days followed by a 14- day rest as maintenance therapy.
  • The serum CEA elevated 13 months after the treatment, and the patient received a reduced course and two-course S-1/CDDP therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Biopsy. Carcinoembryonic Antigen / blood. Drug Combinations. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701855.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Takahashi T, Saikawa Y, Kubota T, Akiba Y, Shigematsu N, Yoshida M, Otani Y, Kumai K, Hibi T, Kitajima M: Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation. Jpn J Clin Oncol; 2003 Nov;33(11):584-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation.
  • A 76-year-old male was diagnosed with stage IV (cT4, cN2, cP0, cH0, cM0) gastric carcinoma with a type 3 tumor in the cardia with lymph node metastases, determined by gastrofiberscope and abdominal computed tomography (CT).
  • The patient was treated with chemotherapy consisting of S-1 and low-dose cisplatin (CDDP) during the first cycle (3 weeks).
  • In the second cycle, radiation therapy (2 Gy/day for 5 days/week) was initiated along with the chemotherapy.
  • The second cycle was stopped at a total radiation dose of 48 Gy due to grade 3 thrombocytopenia and grade 2 leukocytopenia.
  • Examination after this treatment showed remarkable reduction of tumor volume in the primary lesion and lymph nodes, which was defined as a partial response (PR).
  • At this time, no gastric cancer cells were detected in the resected specimen, including the primary lesion and lymph nodes, confirming a pathological complete response (CR grade 3).
  • Thus, the chemo-radiation treatment regimen described here may be a potent tool to control advanced gastric carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Gastroscopy. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Radiotherapy Dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14711984.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH: Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg; 2001 Aug;25(8):985-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial.
  • Previous analysis of this prospective randomized trial and meta-analysis of published randomized trials of adjuvant intraperitoneal chemotherapy demonstrated improved survival in patients with advanced gastric cancer.
  • Simple criteria applicable at the time of surgery for patient selection were sought in this analysis.
  • From 1990 to 1995 a series of 248 patients with biopsy-proven gastric cancer were randomized intraoperatively to receive early postoperative intraperitoneal mitomycin C and 5-fluorouracil (125 patients) versus surgery only (123 patients).
  • Gastric resection plus early postoperative intraperitoneal chemotherapy showed improved overall survival compared to surgery only (54% and 38%, respectively; p = 0.0278).
  • There were statistically significant differences in patients with stage III (57% and 23%, respectively; p = 0.0024) and in those with stage IV (28% and 5%, respectively; p = 0.0098) gastric cancer.
  • The improvement in survival rate was statistically significant for the subgroup of patients with gross serosal invasion (52% and 25%, respectively; p = 0.0004) and patients with lymph node metastasis (46% and 22%, respectively; p = 0.0027).
  • Gross serosal invasion with or without frozen section evaluation of lymph nodes can be used as the major selection criteria for early postoperative intraperitoneal chemotherapy of advanced gastric cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Mitomycin / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infusions, Parenteral. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Postoperative Complications / epidemiology. Prospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2002 Dec;26(12):1532; author reply 1532-3 [12297932.001]
  • (PMID = 11571980.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


9. Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H: Unusual survival for more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer; 2002;5(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual survival for more than 2 years with peritoneal metastases of gastric cancer.
  • We report a patient with peritoneal metastases who was successfully treated with a novel oral fluoropyrimidine anticancer drug, TS-1, as first-line chemotherapy.
  • The patient was a 72-year-old man who had undergone curative resection for type 4 gastric cancer with peritoneal dissemination that was located only at the greater omentum.
  • Final findings were P1, T4, N1, and stage IV.
  • Eighteen months after the gastrectomy, his cancer recurred with peritoneal metastases; these were diagnosed by the presence of multiple stenoses of the colon, an abdominal mass, and elevated levels of the serum tumor markers, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9.
  • Two courses of the treatment resulted in a marked reduction of the abdominal tumor, without severe toxicity.
  • Two years after the onset of the peritoneal metastases, the patient is alive without any sign of progressive disease.
  • Our report is the first to demonstrate the advantages of TS-1 as chemotherapy for the treatment of peritoneal metastasis of gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / secondary. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Male. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12021860.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


10. Akagi J, Masuda Y, Takai E, Takemoto T, Fukami K, Yagishita Y: [Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation]. Gan To Kagaku Ryoho; 2008 Feb;35(2):295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation].
  • A 72-year-old female patient with type 5 gastric cancer in the upper gastric region underwent surgery.
  • Due to paraaortic lymph node metastasis (#16a1, #16a2) and peritoneal metastasis, total gastrectomy and D0 lymph node dissection were performed.
  • Surgical and pathological findings were poorly differentiated adenocarcinoma, INFbeta, pT3(SE), PM (-), DM (-), ly0, v2, sN3 (#7, #9, #16a1-a2), M0, stage IV.
  • The patient was administered S-1 for 2 weeks at 80 mg/day, received 24-hour continuous intravenous infusion of 80 mg/day on day 8, and then discontinued chemotherapy for 2 weeks, which was regarded as one course.
  • After one course, CT scan showed that the paraaortic lymph node metastasis had almost entirely disappeared.
  • However, due to grade 3 neutropenia, and grade 2 nausea and anorexia in the first course, the treatment was changed to oral administration of UFT (400 mg/day) , which was discontinued one month later due to anorexia.
  • This case suggests that reduction surgery combined with a S-1 regimen is an effective treatment for long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aorta / drug effects. Aorta / pathology. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281768.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Hama N, Kashiwazaki M, Ebisui C, Okubo K, Akitake H, Ohtsuka M, Yamanaka C, Maekawa T, Yoshioka S, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of advanced gastric cancer with liver metastases resected successfully after S-1 monotherapy and S-1/CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2330-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with liver metastases resected successfully after S-1 monotherapy and S-1/CDDP combination chemotherapy].
  • The patient was a 75-year-old man, who was diagnosed with type 3 gastric cancer with solitary liver metastasis whose diameter was 12 mm.
  • Distal gastrectomy with D2 lymph node dissection was performed in June 2008.
  • S-1 monotherapy (120 mg/day, day 1-28/42 days) for liver metastasis started as the first-line chemotherapy.
  • After 3 courses, the diameter of liver metastasis enlarged to 22 mm.
  • Moreover, S-1 and CDDP combined chemotherapy (S-1: 120 mg/day, day 1-21/ 35 days, CDDP: 60 mg/m2, day 8/35 days) was performed as the second-line chemotherapy, nevertheless the diameter of liver metastasis enlarged to 26 mm.
  • No distant metastasis without solitary liver tumor was observed for 6 months after gastric resection, so a partial hepatic resection was performed in February 2009.
  • Five months after the operation, the patient is doing well and shows no signs of recurrence of the cancer.
  • A combination gastrectomy with D2 lymphadenectomy and postoperative chemotherapy was considered to be a radical treatment for H1, Stage IV gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Drug Combinations. Hepatectomy. Humans. Male

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037412.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Iwatani Y, Shimada Y, Ohshima T, Kusunoki N, Yamazaki T, Miyazaki N: [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer]. Gan To Kagaku Ryoho; 2001 Aug;28(8):1129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
  • We report the a case of 60-year-old male whose final finding was curability C and stage IV scirrhus type gastric cancer because of N3, CY1 and DM (+) treated with a novel oral anticancer drug composed of tegafur (FT), Gimeracil (CDHP) and Oteracil Potassium (Oxo) in a molar ratio of 1:04:1 after operation.
  • This drug was administered orally twice daily after meals at a dose of 80 mg/body/day.
  • One cycle consisted of consecutive administration for 28 days and 14 days rest, and this treatment cycle was repeated twice.
  • Postoperative abdominal CT showed swollen paraaortic lymph nodes regarded as metastasis.
  • It was considered that this anticancer drug composed of FT, CDHP and Oxo was effective to scirrhus type gastric cancer and useful as an adjuvant chemotherapy in view of the patient's living quality.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Signet Ring Cell / drug therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Postoperative Care

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11525030.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Saikawa Y, Kubota T, Takahashi T, Akatsu Y, Nakamura R, Yoshida M, Shigematsu N, Otani Y, Kumai K, Hibi T, Kitajima M: Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncol Rep; 2005 May;13(5):865-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is chemoradiation effective or harmful for stage VI gastric cancer patients?
  • We aim to clarify beneficial effect of pre-operative radiation with chemotherapy in highly advanced gastric cancer patients, evaluating histological response, toxicity and patients' quality of life (QOL).
  • We used pre-operative radiation with S-1 and low-dose cisplatin to treat 8 patients with highly advanced gastric cancer (clinical stage IV) in a pilot study.
  • Clinical staging after therapy showed 5 PRs (partial response), 2 NCs (no change), and 1 PD (partial disease) following evaluation of the primary tumor and suspicious metastatic lesions in the lymph nodes, esophagus, liver, and peritoneum, for a response rate of 62.5% (5/8 cases).
  • The survival analysis showed that 5 out of the 8 patients died within 10 months after initiating therapy, while 3 patients are alive without recurrence at 15, 18, and 30 months after therapy, suggesting a relatively good outcome for clinical stage IV gastric cancer.
  • All cases showed grade 2-4 bone marrow suppression toxicity and/or grade 0-2 gastro-intestinal toxicity, while 5 out of 8 patients (62.5%) showed improvement in appetite loss at the end of the therapy, indicating that the patients' quality of life (QOL) was preserved.
  • Chemoradiation may be a powerful regimen for obtaining histological response with tolerable toxicity and improved QOL in highly advanced gastric cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Radiotherapy / adverse effects. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Quality of Life. Survival Analysis. Treatment Outcome


14. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • A resected case of gastric cancer is described.
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • Radical resection was not indicated, and we administered the following combination chemotherapy with TS-1 and CDDP.
  • 120 mg/day of TS-1 was orally administered for 3 weeks followed by 2 drug-free weeks as 1 course and 9 5 mg (60 mg/m(2)) of CDDP was administered intravenously on day 8.
  • One year after the operation, the patient is still alive without recurrence and metastasis.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Ojima H, Araki K, Kato T, Okamura K, Manda R, Hirayama I, Hosouchi Y, Nishida Y, Kuwano H: Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1385-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer.
  • BACKGROUND: The characteristics of stage II gastric cancer according to the Japanese Classification of Gastric Cancer (JCGC) were examined and the high-risk factors predicting poor prognosis were detected.
  • PATIENTS AND METHODS: In total, 107 patients, who underwent clinically curative gastrectomy with D2 lymphadenectomy for stage II gastric cancer, were included.
  • Survival curves of the depth of invasion, lymph node metastasis, the ratio of involved: resected lymph nodes and chemotherapy treatment were compared.
  • RESULTS: The survival curves were related to tumor invasion depth and lymph node metastasis.
  • The ratio of involved resected lymph nodes was a good prognostic indicator compared to the classification of regional lymph node metastasis (N classification).
  • Survival rates with adjuvant chemotherapy were slightly higher than without adjuvant chemotherapy, but the difference was not significant.
  • CONCLUSION: pT2pN1 (stage II) gastric cancers according to the JCGC, especially pSSpN1 cases, included stage IIIB and IV gastric cancers according to the International Union Against Cancer / American Joint Committee on Cancer (UICC/AJCC); therefore, the prognosis of these might be poor.
  • With pSSpN1 cases, according to the JCGC, anticancer chemotherapy equivalent to that required for stage III gastric cancer cases is necessary.
  • [MeSH-major] Stomach Neoplasms / classification. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619548.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Maruyama M, Nagahama Y, Sato E, Maruyama S, Sanada T, Koide A, Ohhinata R, Shima Y, Ebuchi M: [Influence of intraperitoneal chemotherapy to a recurrence pattern of gastric cancer with serosal exposure]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1946-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of intraperitoneal chemotherapy to a recurrence pattern of gastric cancer with serosal exposure].
  • We analyzed a recurrence pattern and prognosis of 42 gastric cancer cases with histological serosal exposure of cancer and without macroscopical residual cancer in the operation.
  • These cases received adjuvant MTX-5-FU chemotherapy intraperitoneally.
  • Twenty four patients showed a recurrence of gastric cancer.
  • Seventeen patients (71%) developed peritoneal seeding, which means intraperitoneal chemotherapy made no influence to the pattern of recurrence of gastric cancer with serosal invasion.
  • All of the recurred patients with Stage II and IIIA gastric cancer and about 60% of the recurred patients with Stage IIB and IV developed peritoneal metastasis.
  • Intraperitoneal chemotherapy of MTX-5-FU did not touch the pattern of recurrence of gastric cancer with serosal invasion, but the analysis of the prognosis revealed a possibility of improvement of the prognosis.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secretion. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219860.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Tazawa K, Matsui K, Morita S, Yoshida T, Shinbo M, Yamagishi F, Yamada A, Tsukada K: [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1869-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy].
  • We reported a case of unresectable gastric cancer presenting pylorus stenosis treated orally by S-1 therapy in a 72-year-old man who underwent gastrojejunostomy.
  • Detailed examination showed gastric cancer with pylorus stenosis.
  • After insertion of the naso-gastric tube with washing, a laparotomy was done.
  • The operative findings revealed sT3, sN2, sP1, sH0 and sM1 (metastases of No. 14a lymph nodes invading the super mesenteric artery and pancreas) as an unresectable case with stage IV.
  • After the operation, intake therapy of S-1 was started (80-100 mg/body/dayx28 days).
  • After 2 courses of the therapy, gastrointestinal fiber showed clinically a partial response of the main tumor.
  • After 3 courses of this treatment, the tumor presented multiple liver metastases as a clinically progressive disease state.
  • Paclitaxel therapy was conducted at a dose of 80 mg/body/weekx3 timesx2 courses.
  • The patient had no effective benefits from the treatment and died of the cancer.
  • He had survived 9 months, and the intervals of the intake and home stay were 7.5 months and five months, respectively, after the operation with no side effect of the chemotherapy.
  • Survival was no longer than for patients only operated without S-1 therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Gastric Bypass. Lymph Nodes / pathology. Oxonic Acid / administration & dosage. Pylorus / pathology. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Constriction, Pathologic. Drug Administration Routes. Drug Combinations. Humans. Lymphatic Metastasis. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


18. Kwon HC, Kim MC, Kim KH, Jang JS, Oh SY, Kim SH, Kwon KA, Lee S, Lee HS, Kim HJ: Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol; 2010 Dec;6(4):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
  • We evaluated the efficacy and toxicity of adjuvant chemoradiation versus chemotherapy in completely resected locally advanced gastric cancer.
  • METHODS: Patients with stage IIIA, IIIB and IV (without metastasis) gastric cancer were treated with chemoradiation and 5-fluorouracil/cisplatin (FP) (arm A) or FP (arm B).
  • CONCLUSION:   We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Liver Neoplasms / therapy. Lymph Node Excision. Ovarian Neoplasms / therapy. Peritoneal Neoplasms / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Capecitabine. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Follow-Up Studies. Gastrectomy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • [CommentIn] Asia Pac J Clin Oncol. 2011 Jun;7(2):93-5 [21585687.001]
  • (PMID = 21114777.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Zhao X, Huang K, Zhu Z, Chen S, Hu R: Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol; 2007 Aug;22(8):1317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer.
  • BACKGROUND: The relationship between the expression of leptin in the tissue of gastric cancer and the clinicopathological features as well as patients' outcome were investigated.
  • METHODS: Sixty-one gastric cancer specimens were investigated by immunohistochemical studies with anti-leptin and anti-vascular endothelial growth factor (VEGF) antibodies and by monitoring patients for at least 3 years after surgery.
  • RESULTS: A positive rate of leptin expression was significantly associated with Borrmann classification (Borrmann type 1 and type 2 68.2% vs Borrmann type 3 and type 4 or unclassified 35.3%), tumor histology (well differentiated tumors 87.5% vs poorly differentiated tumors 48.9%), lymph node metastasis (with 69.0% vs without 36.8%) and stage (stage III + IV 69.0% vs stage I + II 36.8%).
  • The Cox proportional hazards model identified serosal involvement, tumor size, metastasis, tumor histology, leptin expression, lymph node metastasis, age and postoperative chemotherapy as significant prognostic factors.
  • CONCLUSIONS: The expression of leptin in the tissue of gastric cancer was significantly associated with tumor histology, Borrmann classification, lymph node metastasis and stage of gastric cancer.
  • In patients with poorly differentiated gastric cancer, a poor prognosis was found in those with a strong expression of leptin.
  • [MeSH-major] Carcinoma / metabolism. Leptin / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Humans. Immunohistochemistry. Lymphatic Metastasis. Survival Rate. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559372.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Leptin; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


20. Okabe T, Ohya T, Matsumoto H, Tago K, Totsuka O, Numaga Y, Higuchi T, Iesato H, Yokomori T, Kawate S, Takeyoshi I: [A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine]. Gan To Kagaku Ryoho; 2009 Jan;36(1):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine].
  • A 68-year-old man underwent total gastrectomy for Type 3 gastric cancer with liver metastasis.
  • The final finding was T3(SE), N1, H1, P0, CY0(class IV), Stage IV, Cur C.
  • After surgery, he was treated with combination chemotherapy of weekly paclitaxel(PTX)/doxifluridine(5'-DFUR).
  • After 2 courses, the tumor marker level normalized, and the size of the liver metastasis was remarkably decreased.
  • After 5 courses, a CT scan revealed the liver metastasis had disappeared, and he has now survived without recurrence after the disappearance of the liver metastasis.
  • This therapy may thus be effective in the treatment of advanced gastric cancer following non-curative operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Humans. Male. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151575.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 039LU44I5M / Floxuridine; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


21. Shibata N, Watari J, Satoh T, Tanabe H, Fujiya M, Yasuda A, Saitoh Y, Yokota K, Kohgo Y, Kino Y, Matsuda M, Kasai S: [Two cases of stage IV type 4 gastric cancer with good response to TS-1]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1455-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of stage IV type 4 gastric cancer with good response to TS-1].
  • We report two patients with Type 4 gastric cancers having multiple lymph node metastasis and carcinomatosa which responded well to TS-1.
  • After administration of TS-1 orally for two courses, both patients showed improved extension of the gastric wall and almost complete reduction of metastatic lymph nodes.
  • In case 2, colonic stenosis due to peritonum carcinomatosa disappeared after chemotherapy with TS-1.
  • It was confirmed histopathologically that TS-1 was effective against the primary sites and lymph node metastasis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


22. Jingu K, Sasagawa K, Kagaya A, Ochiai T: [A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy].
  • We report herein a case with stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy.
  • A 65-year-old female was diagnosed as having type 3 gastric cancer with para-aortic lymph node metastases.
  • Histopathological examination revealed that the tumor was poorly-differentiated adenocarcinoma with para-aortic lymph nodes metastases and completely resected.
  • After the operation,she was treated by adjuvant chemotherapy with TS-1.
  • In March of 2004, she suffered from hematuria, and a CT scan revealed para-aortic lymph nodes metastases and left kidney metastasis.
  • Then, she was treated by a weekly infusion of paclitaxel as second-line chemotherapy.
  • Therefore, weekly paclitaxel therapy was considered to be one of the promising second-line chemotherapies for advanced or recurrent gastric cancer previously treated by TS-1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352940.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement